AllPennyStocks.com SRRK Stock Gains After Company Drops Troubled Novo Nordisk-Owned Plant From FDA Filing
This section contains press releases and other materials from third parties (including paid content). AllPennyStocks.com has not reviewed this content. Please see our disclaimer.

SRRK Stock Gains After Company Drops Troubled Novo Nordisk-Owned Plant From FDA Filing

The company said it has, in accordance with FDA guidance, removed Catalent Indiana—a fill-finish plant now owned by Novo Nordisk—from its U.S. biologics license application for apitegromab.

Other Penny Stock Movers

65,000 Patients a Year, Zero Approved Drugs, One Phase 3 Trial
$4.5 Million Could Unlock a Major Cannabis Market
Chilean Gold Developer Gains 15% on Final Permit Clearance
Most Popular
{{ index + 1 }}


Back to Top